Vagal Nerve Stimulation for Nonneurological Diseases: An Overview

Authors

  • Raghu Samala Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
  • Ramesh Sharanappa Doddamani Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi 110029, India
  • Rajesh Meena Department of Neurosurgery, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
  • Mohit Agrawal Department of Neurosurgery, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
  • Dattaraj Sawarkar Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
  • Deepak Agrawal Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
  • Poodipedi Sarat Chandra Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
  • Manjari Tripathi Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Keywords:

angina, heart failure, inflammatory bowel disease, peripheral arterial disease, rheumatoid arthritis, sepsis

Abstract

Vagal nerve stimulation (VNS) is US Food and Drug Administration approved treatment for drug refractory epilepsy and major depression. In vivo research showed that VNS has anti-inflammatory properties and has a role in inflammatory conditions such as inflammatory bowel disease, rheumatoid arthritis, sepsis, lung and bowel injuries, and in patients with head injury. It is also shown that VNS can restore the homeostasis between the sympathetic and parasympathetic systems. This property is made use of in heart failure, angina, and peripheral arterial disease. Cluster headache and migraine are the other conditions. In this review, we describe the indications along with the mechanisms in various clinical conditions other than epilepsy and the associated outcomes.

Downloads

Published

2021-08-20

Issue

Vol. 5 No. 1 (2021): Journal of Peripheral Nerve Surgery

Section

Review